A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics
Status:
COMPLETED
Trial end date:
2025-01-26
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label study aim to evaluate the efficacy and safety of IBI112 in Chinese participants with plaque psoriasis who were treated with biologics and switched to IBI112. The study will enroll 160 participants who were diagnosed with plaque psoriasis. The whole study consists of 4 weeks of screening, 32 or 36 weeks of treatment and a safety follow-up visit at Week 44.